AI-enabled precision medicine
Our partnership model with biopharma focuses on developing biomarker-driven strategies using our AI intelligence platform uncovering opportunities that were undetectable with conventional approaches. We license or co-develop clinical-stage therapeutics to ensure these highly efficacious drugs reach patients that need them most.
Vanguard in therapeutics
Pathos was borne out of the idea that AI can transform each step of the drug development process, from patient selection, biomarker development, trial design, and clinical trial operations to bring precision medicines to market at an unimaginable pace.